ROSACEA DEVELOPMENT | TRIGGER CONTROL | REDNESS CONTROL
THREAD VEINS & TISSUE CHANGES | UK EVALUATION
THREAD VEINS & TISSUE CHANGES | UK EVALUATION
TRIGGER CONTROL
This section contains information on:
- Raising Trigger Tolerance Thresholds
- Reducing The Skins Inflammatory Response Once Triggered
- Secondary Inhibitory Effect on Immune Response
RAISING TRIGGER TOLERANCE THRESHOLDS
Raising trigger tolerance thresholds is partly achieved through management of the cascade process and increasing the skin tolerance to triggers so that sufferers thresh-hold levels increase over time, thereby raising the level of triggering needed before the dilation and chemical cascade are initiated. Also increasing better cellular control of the chemical release can reduce the length and the intensity of the episode once trigger tolerance has been exceeded.
Other ways of increasing tolerance is to support the vascular structure and the peri-vessel area surrounding the capillaries by providing nourishment and support. Also, reducing free radical damage by supplying powerful antioxidants can promote healthy skin, which is more resistant to triggering.
Once the trigger has initiated a response then by managing the chemical response cascade and minimising can reduce the level of response at a cellular level as discussed elsewhere but also one can try to reduce the secondary response from the body’s immune system.
REDUCING THE INFLAMMATORY RESPONSE ONCE TRIGGERED
When the trigger reaches a level that exceeds the tolerance levels in the skin, inflammatory chemicals such as interleukin-1 alpha are released which cause prolonged reddening and inflammation. In an experiment Synchrorose Fast showed an ability to reduce the amount of the chemical released and as a consequence may result in less inflammation in intensity and duration. The experiment which used a chemical known as SLS as the stimulating trigger showed less inflammatory chemical was released in the presence of the active ingredients in Synchrorose Fast than when exposed to SLS alone. This suggests Synchrorose can cause a reduction in the body’s inflammatory response to reddening triggers.
Dexamethosone is used in hospital to calm the immune response to chemicals etc and the activation of the immune system is often measured by the level of expression of CD80 and CD 86 and the key ingredients in Synchrorose® have been shown to inhibit this expression in experiments. This can have a benefit in that once the tolerance to triggers is exceeded then it is important to reduce the level of immune response to minimise symptom development and help in desensitisation. In the experiment below, Nickel Sulphate was the sensitising agent used.
SECONDARY INHIBITORY EFFECT ON IMMUNE RESPONSE
One further way one can reduce the process is to reduce the body's response once the erythema process has been triggered. Local chemical cascade stimulates the body's immune response system to the damage and with plasma fluid and white cells flooding into the affected area. This further exacerbates and prolongs the reddening and inflammation. If one can reduce the level of the immune response, this can give another level of control.
Dexamethosone is used in hospital to calm the immune response to chemicals etc and the activation of the immune system is often measured by the level of expression of CD80 and CD 86 and the key ingredients in Synchrorose® have been shown to inhibit this expression in experiments. This can have a benefit in that once the tolerance to triggers is exceeded then it is important to reduce the level of immune response to minimise symptom development and help in desensitisation. In the experiment below Nickel Sulphate was the sensitising agent used.
